E. D. Laryushkina
Research Subjects
E. D. Laryushkina has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- E. V. Kuznetsova
Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department
3 shared publications - Marina Vladimirovna Zhuravleva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Tatiana R. Kameneva
Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology
3 shared publications - Alexander Valerevich Kryukov
Russian Medical Academy of Continuous Professional Education; Filatov City Clinical Hospital No. 15
2 shared publications 105187 City Clinical Hospital Named After F.I. Inozemtsev
1 shared publication123423 City Clinical Hospital No. 67 Named After L.A. Vorokhobov
1 shared publication
Latest Publications
- Open Access
- 26 December 2023
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 68 (7-8) , 90-98
Drug Cost Optimization Using Evidence-Based Decision Support Systems
The article presents an overview of specialized medical information systems that perform ABC/VEN analysis. It provides a comparison of specific examples, describes their advantages and disadvantages, as well as the possibility of automating the processes of searching for information on the proven effectiveness of drugs, selecting alternative drugs within one ATC group, selecting alternative drugs within the framework of the current clinical recommendations of the Ministry of Health of the Russian Federation, assessing drug-drug interactions, as well as the reference information from the instructions for use of the drugs.
- 26 December 2023
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 68 (7-8) , 90-98
Open AccessDrug Cost Optimization Using Evidence-Based Decision Support Systems
The article presents an overview of specialized medical information systems that perform ABC/VEN analysis. It provides a comparison of specific examples, describes their advantages and disadvantages, as well as the possibility of automating the processes of searching for information on the proven effectiveness of drugs, selecting alternative drugs within one ATC group, selecting alternative drugs within the framework of the current clinical recommendations of the Ministry of Health of the Russian Federation, assessing drug-drug interactions, as well as the reference information from the instructions for use of the drugs.
- Open Access
- 31 July 2023
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 42-52-52
Economic aspects of the fixed combinations of lipid lowering medicines in group risks patients
Relevance. Cardio-vascular diseases (CVD) are the one of the main reasons of mortality and disability. Hypercholesterinemia is a factor of CVD progression, and thus it should be corrected. Combination of statin + ezetemib is an effective option of a medical technology for this purpose. Pharmacoeconomic analysis of rosuvastatin and ezetemib fixed combination (FC) has been performed in this work in comparison with free combination (FrC) of these drugs.Materials and methods. Modelling of FC vs FrC in groups of CVD risk has been performed on 1–5 years horizon based on the local epidemiologic published data with aim of economic analysis. Efficacy of FC and FrC, direct medical costs, including cost of drugs, hospitalizations etc. were taken into account also. ICER has been calculated and compared with willingness to pay.Results. FC usage instead FrC can prevent 2960–3055 deaths and 8880–9164 admissions to hospital caused CVD. FC decrease of ambulance cost as well as others direct medical expenditures in compare with FrC treatment on 9,3 bln RUR per 5 years. ICER has been calculated and has negative (dominant) result.Conclusion. FC usage is an economic dominant technology in compare with FrC for hypercholesterolemia control.
- 31 July 2023
- Published by Publishing House OKI in Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice
- No. 2,p. 42-52-52
Open AccessEconomic aspects of the fixed combinations of lipid lowering medicines in group risks patients
Relevance. Cardio-vascular diseases (CVD) are the one of the main reasons of mortality and disability. Hypercholesterinemia is a factor of CVD progression, and thus it should be corrected. Combination of statin + ezetemib is an effective option of a medical technology for this purpose. Pharmacoeconomic analysis of rosuvastatin and ezetemib fixed combination (FC) has been performed in this work in comparison with free combination (FrC) of these drugs.Materials and methods. Modelling of FC vs FrC in groups of CVD risk has been performed on 1–5 years horizon based on the local epidemiologic published data with aim of economic analysis. Efficacy of FC and FrC, direct medical costs, including cost of drugs, hospitalizations etc. were taken into account also. ICER has been calculated and compared with willingness to pay.Results. FC usage instead FrC can prevent 2960–3055 deaths and 8880–9164 admissions to hospital caused CVD. FC decrease of ambulance cost as well as others direct medical expenditures in compare with FrC treatment on 9,3 bln RUR per 5 years. ICER has been calculated and has negative (dominant) result.Conclusion. FC usage is an economic dominant technology in compare with FrC for hypercholesterolemia control.
- 1 January 2022
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 11 (2)
Evaluation of clinical outcomes of COVID-19 in patients taking remdesivir in complex therapy in routine clinical practice
Оценка клинических исходов СOVID-19 у пациентов, получавших ремдесивир в составе комплексной терапии в рутинной клинической практике
- 1 January 2022
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 11 (2)
Evaluation of clinical outcomes of COVID-19 in patients taking remdesivir in complex therapy in routine clinical practice
Оценка клинических исходов СOVID-19 у пациентов, получавших ремдесивир в составе комплексной терапии в рутинной клинической практике